The FDA approved Abecma, the first cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy.
Read more: FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma